Monoclonal antibody

Seismic Bio Partners With Twist Bioscience for Discovery and Optimization of Antibodies

Retrieved on: 
Tuesday, August 4, 2020
Research, Pharmaceutical, Oncology, Technology, Genetics, Clinical trials, Science, Nanotechnology, Biotechnology, Stem cells, Other Science, Health, Medical specialties, Immunology, Clinical medicine, Medicine, Monoclonal antibody, Bispecific monoclonal antibody, Antibody, the Hyperimmune Libraries, Seismic Bio, Inc., Twist Biopharma, Twist Bioscience Corporation

Seismic Bio will then use these monoclonal antibodies as building blocks to create robust bispecific antibody therapeutics.

Key Points: 
  • Seismic Bio will then use these monoclonal antibodies as building blocks to create robust bispecific antibody therapeutics.
  • Seismic Bio will pay Twist technology activity fees as well as milestones for all compounds discovered through the agreement.
  • Seismic Bio, Inc. is an emerging preclinical stage biopharmaceutical company developing bispecific therapeutic antibodies that enable controlled activation of the immune system to fight cancer.
  • This library of libraries gives our partners an integral and unbiased resource for antibody therapeutic discovery and optimization.

COVID-19 Impacts: Biosimilar Monoclonal Antibodies (mAbs) Market will Accelerate at a CAGR of over 30% through 2020-2024|Increase in Prevalence of Chronic Diseases to Boost Growth| Technavio

Retrieved on: 
Tuesday, August 4, 2020
Biotechnology, Pharmaceutical, Health, Oncology, Medical specialties, Biotechnology, Life sciences, Medicine, Immunology, Biosimilar, Drugs, Monoclonal antibody, Mab, Coronavirus disease

The report offers an up-to-date analysis regarding the current market scenario, latest trends and drivers, and the overall market environment.

Key Points: 
  • The report offers an up-to-date analysis regarding the current market scenario, latest trends and drivers, and the overall market environment.
  • Please Request Free Sample Report on COVID-19 Impact
    What was the value of the biosimilar monoclonal antibodies (mAbs) market in 2019?
  • An increase in the prevalence of chronic diseases has been instrumental in driving the growth of the market.
  • Biosimilar monoclonal antibodies (mAbs) Market 2020-2024: Segmentation
    Biosimilar monoclonal antibodies (mAbs) Market is segmented as below:

IPA's Human Anti-SARS-CoV-2 Therapeutic Antibodies Demonstrate Synergistic Neutralization

Retrieved on: 
Friday, July 31, 2020
Medical specialties, Immunology, Medicine, Clinical medicine, Monoclonal antibody, Humanized antibody, Antibody, Neutralizing antibody, Hybridoma technology, Recombinant antibodies, Single-domain antibody

Previously, IPA confirmed the identification of numerous therapeutic antibodies derived from multiple species (human, llama, Ligand's humanized OmniRat, and wild-type rabbits) demonstrating potent, in vitro neutralizing activity.

Key Points: 
  • Previously, IPA confirmed the identification of numerous therapeutic antibodies derived from multiple species (human, llama, Ligand's humanized OmniRat, and wild-type rabbits) demonstrating potent, in vitro neutralizing activity.
  • These functional antibodies were discovered using the Company's DeepDisplay phage technology, B Cell Select and Single Step Hybridoma platforms.
  • The functional antibodies discovered to date bind to multiple regions of the SARS-CoV-2 spike protein.
  • ImmunoPrecise is a full-service, therapeutic antibody discovery company utilizing species agnostic, multi-format, characterized and engineered, human monoclonal antibodies, on an abbreviated timeframe.

BioFactura Awarded $1 Million SBIR Contract for Development of a Marburg Virus Therapeutic

Retrieved on: 
Thursday, July 30, 2020
Medical specialties, Medicine, Clinical medicine, Biological weapons, Tropical diseases, Zoonoses, Animal virology, Filoviridae, Marburg virus disease, Marburg virus, Ebolavirus, Monoclonal antibody

With so much focus on Ebolavirus over the last few years, MARV antibody development efforts have lagged considerably and few MARV-specific mAbs have been described.

Key Points: 
  • With so much focus on Ebolavirus over the last few years, MARV antibody development efforts have lagged considerably and few MARV-specific mAbs have been described.
  • Dr. Darryl Sampey, President and CEO of BioFactura, stated, "This Chem-Bio Defense Phase II award builds upon our successful early development of a highly productive StableFast cell line during the SBIR Phase I contract.
  • "This government contract for the development of a novel Marburg virus therapeutic countermeasure is the result of continued efforts to create highly effective therapeutics that can be deployed in the event of a biological threat.
  • For over 15 years, BioFactura has been advancing life-saving medicines from the research bench to the patient using its innovative drug development and manufacturing technologies.

NEJM Study Demonstrates Safety and Efficacy of First Novel Monoclonal Antibody Specifically Developed to Treat Yellow Fever

Retrieved on: 
Wednesday, July 29, 2020
Health, Infectious diseases, General Health, Clinical trials, Research, Science, Biotechnology, Medical specialties, Infectious diseases, Clinical medicine, RTT, Vaccine-preventable diseases, Immunology, Biological weapons, Tropical diseases, Monoclonal antibody, Yellow fever, Typhoid fever

IND-enabling studies for the development of Tychans successful mAb for yellow fever took seven months from design to first-in-human infusion.

Key Points: 
  • IND-enabling studies for the development of Tychans successful mAb for yellow fever took seven months from design to first-in-human infusion.
  • The results of this study set the stage for a phase 2 trial in geographies endemic for yellow fever, to assess the efficacy of TY014 as the first treatment for yellow fever.
  • The strategy is to accelerate the study of TY014 for yellow fever as the disease has a mortality rate of 20 50%.
  • TY014 is the first monoclonal antibody designed and engineered to treat yellow fever virus infected patients to enter the clinic.

Spring Bank Pharmaceuticals and F-star Therapeutics Agree to Combine to Pursue Mission of Creating Next Generation Immunotherapies

Retrieved on: 
Wednesday, July 29, 2020
Medical specialties, Life sciences, Health, Immunology, Biotechnology, Immune system, Monoclonal antibody, Bispecific monoclonal antibody, Antibody, Ladenburg Thalmann, Biopharmaceutical

Through its proprietary tetravalent, bispecific antibody (mAb) format, F-stars mission is to generate highly differentiated, best-in-class drug candidates with monoclonal antibody-like manufacturability.

Key Points: 
  • Through its proprietary tetravalent, bispecific antibody (mAb) format, F-stars mission is to generate highly differentiated, best-in-class drug candidates with monoclonal antibody-like manufacturability.
  • The Spring Bank directors and officers have signed support agreements committing them to vote in favor of the transaction.
  • Ladenburg Thalmann & Co. Inc. is acting as exclusive financial advisor and Lowenstein Sandler is serving as legal counsel to Spring Bank.
  • Spring Bank Pharmaceuticals, Inc.is a clinical-stage biopharmaceutical company engaged in the discovery and development of a novel class of therapeutics using its proprietary small molecule nucleotide platform.

Xencor to Host Second Quarter 2020 Financial Results Webcast and Conference Call on August 4, 2020

Retrieved on: 
Tuesday, July 28, 2020
Oncology, Health, Clinical trials, Research, Science, Pharmaceutical, Biotechnology, Medicine, Immune system, Immunology, Biotechnology, Monoclonal antibody, Health care, Biology

Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer and autoimmune disease, today announced that it will release second quarter 2020 financial results after the market closes on Tuesday, August 4, 2020.

Key Points: 
  • Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer and autoimmune disease, today announced that it will release second quarter 2020 financial results after the market closes on Tuesday, August 4, 2020.
  • Xencor management will host a webcast and conference call the same day at 4:30 p.m.
  • ET (1:30 p.m. PT) to discuss the financial results and provide a corporate update.
  • A live webcast of the conference call will be available under "Events & Presentations" in the Investors section of the Company's website located at www.xencor.com .

Global Antibody Production Market (2020 to 2025) - Growth, Trends, and Forecasts - ResearchAndMarkets.com

Retrieved on: 
Friday, July 24, 2020
Biotechnology, Health, Other Health, Branches of biology, Immunology, Medicine, Clinical medicine, Glycoproteins, Immune system, Biotechnology, Antineoplastic drugs, Antibody, Polyclonal antibodies, Targeted therapy, Monoclonal antibody

The "Antibody Production Market - Growth, Trends, and Forecasts (2020 - 2025)" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Antibody Production Market - Growth, Trends, and Forecasts (2020 - 2025)" report has been added to ResearchAndMarkets.com's offering.
  • The targeted therapy is attaining importance due to its specificity toward cancer cells, while sparing the toxicity to off-target cells.
  • The rising adoption of targeted therapies are expected to propel the overall growth of the antibody production market over the forecast period.
  • The polyclonal antibody segment is expected to be the fastest-growing market, owing to benefits, such as ease of production, low price, and diagnosis of diseases with high proficiency.

Sorrento Enters Into Letter Of Intent To Acquire SmartPharm And Develop Pipeline Of Gene-Encoded Therapeutic Antibodies, Starting With Neutralizing Antibodies To Treat COVID-19 and Cancer Therapeutics

Retrieved on: 
Friday, July 24, 2020
Medical specialties, Immunology, Medicine, Clinical medicine, Monoclonal antibody, Neutralizing antibody, Antibody, Immunogenicity, Coronavirus disease

Sorrento and SmartPharm previously announced a research and development collaboration to encode and express in vivo Sorrento's proprietary SARS-CoV-2 neutralizing monoclonal antibodies utilizing SmartPharm's Gene Mab plasmid nanoparticle platform.

Key Points: 
  • Sorrento and SmartPharm previously announced a research and development collaboration to encode and express in vivo Sorrento's proprietary SARS-CoV-2 neutralizing monoclonal antibodies utilizing SmartPharm's Gene Mab plasmid nanoparticle platform.
  • The initial clinical trial for STI-1499 is expected to be in ICU patients to ensure safety and potentially allow a preliminary look at efficacy.
  • SmartPharm's Gene Mab platform delivers to muscles a novel low-immunogenic DNA plasmid encoded with a therapeutic antibody for long-lasting expression in vivo.
  • "We are very encouraged by the preclinical data generated thus far by our STI-1499 neutralizing antibody against COVID-19," said Henry Ji, Ph.D., CEO of Sorrento Therapeutics.

EpimAb Biotherapeutics Strengthens Scientific Advisory Board with Addition of Professor Mark Smyth

Retrieved on: 
Friday, July 24, 2020
Biotechnology, Manufacturing, Other Manufacturing, Health, Pharmaceutical, Medical specialties, Clinical medicine, Medicine, Herston, Queensland, QIMR Berghofer Medical Research Institute, Monoclonal antibody, Cancer immunotherapy, Bispecific monoclonal antibody

EpimAb Biotherapeutics , an emerging Shanghai-based biopharmaceutical company specializing in bispecific antibodies, today announced the appointment of Professor Mark Smyth to the companys Scientific Advisory Board.

Key Points: 
  • EpimAb Biotherapeutics , an emerging Shanghai-based biopharmaceutical company specializing in bispecific antibodies, today announced the appointment of Professor Mark Smyth to the companys Scientific Advisory Board.
  • Currently a Senior Scientist and the Immunology Department Coordinator at QIMR Berghofer Medical Research Institute, Professor Smyth brings over 20 years of immuno-oncology expertise and research experience to the Scientific Advisory Board.
  • We are very proud to welcome Professor Smyth to EpimAbs Scientific Advisory Board, said Dr. Chengbin Wu, CEO and founder of EpimAb.
  • More recently, Professor Smyth provided new means of classifying natural killer cell subtypes and two new targets for cancer immunotherapy.